[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631522":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":20,"responsibleParty":37,"collaborators":39,"id":43,"slug":44,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":10,"studyType":56,"phases":10,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":70,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Maastricht University Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients wit BCC suspected lesions who underwent LC-OCT imaging",null,"Patients with clinically suspected BCC lesions requiring biopsy who underwent LC-OCT imaging as part of routine clinical care at Mohs Clinics.",[13,18],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Yara Valkenburg, MD","CONTACT","+31(0)43- 387 7295","yara.valkenburg@mumc.nl",{"name":19,"role":15,"phone":16,"phoneExt":10,"email":10},"Klara Mosterd, MD PhD",[21],{"facility":22,"status":10,"city":23,"state":24,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Maastricht University Medical Center +","Maastricht","Limburg","6229HX","Netherlands","NL",{"type":29,"coordinates":30},"Point",[31,32],5.68889,50.84833,{"lat":32,"lon":31},[35,36],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},{"name":19,"role":15,"phone":16,"phoneExt":10,"email":10},{"type":38,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[40],{"name":41,"class":42},"Mohs Klinieken","UNKNOWN","100631522","real-world-evaluation-of-the-implementation-of-lc-oct-in-daily-clinical-practice-100631522",false,"NCT07501780","Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice","Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice: a Retrospective Observational Study","RELI","Inclusion Criteria:\n\n* Patients aged ≥18 years\n* LC-OCT performed as part of diagnostic evaluation between January 2025 and June 2025 at Mohs clinics in the Netherlands\n* Histopathological results (biopsy or excision) and\u002For 6-12 month clinical follow-up data available\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Cases without histopathological confirmation or available follow-up data","ALL","18 Years",{"count":54,"type":55},297,"ESTIMATED","OBSERVATIONAL","Basal cell carcinoma (BCC) is the most common skin cancer in the Netherlands, with incidence rates continuing to rise. The current diagnostic standard combines clinical evaluation and dermoscopy, while biopsy followed by histopathological examination remains the gold standard when uncertainty about the diagnosis persists. However, biopsy is invasive, time-consuming, and costly. Line-field confocal optical coherence tomography (LC-OCT) is a non-invasive imaging technique that has emerged as a promising alternative to biopsy for BCC suspected lesions.\n\nThis retrospective study aims to evaluate the real-world clinical performance of LC-OCT in routine dermatological practice, where it has been integrated into the diagnostic work-up for BCC-suspect lesions.",[59,60,61,62,63,64,65],"Basal Cell Carcinoma of Skin","Optical Coherence Tomography (OCT)","Neoplasms","Neoplasms, Basal Cell","Carcinoma, Basal Cell (BCC)","Real-world Study","Implementation",[67,68,69],"Line-Field Optical Coherence Tomography","Real-world evaluation","Non-melanoma skin cancer","NOT_YET_RECRUITING","2026-03-24",{"date":73,"type":74},"2026-03-30","ACTUAL",{"date":76,"type":55},"2026-03-15",{"date":78,"type":55},"2027-12-01",{"name":5,"class":6},1]